NZ545385A - Prion-specific peptide reagents - Google Patents

Prion-specific peptide reagents

Info

Publication number
NZ545385A
NZ545385A NZ545385A NZ54538504A NZ545385A NZ 545385 A NZ545385 A NZ 545385A NZ 545385 A NZ545385 A NZ 545385A NZ 54538504 A NZ54538504 A NZ 54538504A NZ 545385 A NZ545385 A NZ 545385A
Authority
NZ
New Zealand
Prior art keywords
prion
pathogenic
peptide reagent
conformational
peptide
Prior art date
Application number
NZ545385A
Other languages
English (en)
Inventor
Melissa D Michelitsch
Celine Hu
Ronald N Zuckermann
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Priority to NZ580256A priority Critical patent/NZ580256A/en
Publication of NZ545385A publication Critical patent/NZ545385A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
NZ545385A 2003-08-13 2004-08-13 Prion-specific peptide reagents NZ545385A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ580256A NZ580256A (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents comprising the sequence KKRPKPGG

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49496203P 2003-08-13 2003-08-13
US57036804P 2004-05-12 2004-05-12
US58650904P 2004-07-09 2004-07-09
PCT/US2004/026363 WO2005016127A2 (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents

Publications (1)

Publication Number Publication Date
NZ545385A true NZ545385A (en) 2010-12-24

Family

ID=34198970

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ545385A NZ545385A (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents
NZ580256A NZ580256A (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents comprising the sequence KKRPKPGG

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ580256A NZ580256A (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents comprising the sequence KKRPKPGG

Country Status (13)

Country Link
US (1) US7439041B2 (https=)
EP (1) EP1653844B1 (https=)
JP (3) JP4709149B2 (https=)
KR (1) KR101166012B1 (https=)
AU (2) AU2004264953B2 (https=)
BR (1) BRPI0413495A (https=)
CA (1) CA2535261C (https=)
DK (1) DK1653844T3 (https=)
ES (1) ES2398394T3 (https=)
IL (1) IL173480A0 (https=)
MX (1) MXPA06001588A (https=)
NZ (2) NZ545385A (https=)
WO (1) WO2005016127A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (en) * 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
DK1653844T3 (da) * 2003-08-13 2013-03-11 Novartis Vaccines & Diagnostic Prionspecifikke peptidreagenser
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
WO2006076497A2 (en) 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
MX2007008497A (es) * 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
EP1853915B1 (en) * 2005-02-15 2011-10-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
KR20080048527A (ko) * 2005-09-09 2008-06-02 노파르티스 아게 프리온-특이적 펩토이드 시약
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
WO2008013859A2 (en) * 2006-07-28 2008-01-31 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
WO2008124100A1 (en) * 2007-04-04 2008-10-16 Novartis Ag Prion elisa
ATE530914T1 (de) * 2007-04-04 2011-11-15 Novartis Ag Prionentest
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
US8709472B1 (en) * 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
CA2721982A1 (en) * 2008-04-30 2009-11-05 Novartis Ag Assay for pathogenic conformers
EP2128618A1 (en) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. A process for monitoring the presence of pathogenic agents in biological fluids by nanostructured materials
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
KR102201144B1 (ko) * 2016-05-10 2021-01-11 엘지전자 주식회사 이동 로봇 및 그 제어방법
WO2018005330A1 (en) * 2016-06-27 2018-01-04 Florida State University Research Foundation, Inc. Modified fragments from the octarepeat region of prion protein as hemin binders
US11660325B2 (en) 2016-09-19 2023-05-30 University Of Houston System Compositions and methods of targeting cancer stem cells
JP2021004175A (ja) * 2017-09-04 2021-01-14 国立大学法人東北大学 コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246059A (en) 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE852011T1 (de) * 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
AU738606B2 (en) 1997-02-06 2001-09-20 Enfer Technology Limited Immunological assay for spongiform encephalopathies
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
DE69926742T2 (de) * 1998-04-14 2006-06-14 Sugen Inc Ste20-verwandte proteinkinasen
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
EP1194164B8 (en) 1999-06-23 2007-03-21 IDEXX Laboratories Inc Prion protein peptides and uses thereof
WO2001007479A2 (en) 1999-07-27 2001-02-01 Imperial College Innovations Limited Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
AU5241100A (en) * 1999-09-28 2001-04-30 Universitat Zurich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
CA2405568A1 (en) 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
US6642171B2 (en) * 2000-04-28 2003-11-04 Synuthane International, Inc. Double metal cyanide catalysts containing polyglycol ether complexing agents
IL148202A0 (en) 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
AU6408901A (en) 2000-07-07 2002-01-21 Applied Research Systems Early diagnosis of conformational diseases
GB0103508D0 (en) * 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US7479482B2 (en) * 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
EP1481001A2 (en) 2001-12-10 2004-12-01 Applied Research Systems ARS Holding N.V. Prion inhibiting peptides and derivatives thereof
US7659076B2 (en) 2002-02-28 2010-02-09 Microsens Biophage Limited Binding of pathological forms of prion proteins
NZ536054A (en) 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
US20040208919A1 (en) * 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
EP1534746A2 (en) 2002-08-23 2005-06-01 Copenhagen Biotech Assets APS Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
AU2002342850A1 (en) 2002-10-23 2004-05-13 Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A Prion protein-binding peptide sequences
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
DK1573323T3 (da) 2002-12-03 2012-01-23 Pathogen Removal & Diagnostic Technologies Inc Prion-proteinligander samt fremgangsmåder til anvendelse deraf
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
WO2004090102A2 (en) 2003-04-04 2004-10-21 American Red Cross Prion protein binding materials and methods of use
CA2522483A1 (en) 2003-04-14 2004-10-28 Julia T. Lathrop Method for identifying ligands specific for structural isoforms of proteins
DK1653844T3 (da) * 2003-08-13 2013-03-11 Novartis Vaccines & Diagnostic Prionspecifikke peptidreagenser
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins

Also Published As

Publication number Publication date
US7439041B2 (en) 2008-10-21
DK1653844T3 (da) 2013-03-11
AU2009225337B2 (en) 2012-12-06
NZ580256A (en) 2011-07-29
MXPA06001588A (es) 2006-08-25
JP2010158247A (ja) 2010-07-22
WO2005016127A3 (en) 2006-12-21
HK1090275A1 (en) 2006-12-22
AU2004264953B2 (en) 2009-07-23
KR101166012B1 (ko) 2012-07-23
BRPI0413495A (pt) 2006-10-17
JP4709149B2 (ja) 2011-06-22
AU2009225337A1 (en) 2009-11-05
KR20060066088A (ko) 2006-06-15
WO2005016127A2 (en) 2005-02-24
CA2535261A1 (en) 2005-02-24
EP1653844B1 (en) 2012-12-12
JP2007502120A (ja) 2007-02-08
US20050118645A1 (en) 2005-06-02
CA2535261C (en) 2015-11-24
EP1653844A2 (en) 2006-05-10
JP2013033060A (ja) 2013-02-14
ES2398394T3 (es) 2013-03-15
IL173480A0 (en) 2006-06-11
EP1653844A4 (en) 2009-01-14
AU2004264953A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2009225337B2 (en) Prion-specific peptide reagents
US20090061462A1 (en) Prion-specific peptide reagents
AU2006204705B2 (en) ELISA assays using prion-specific peptide reagents
US20090099343A1 (en) Isolation of pathogenic prions
US20090191571A1 (en) Isolation and Detection of Pathogenic Prions
CN1984669B (zh) 朊病毒特异性的肽试剂
RU2381033C2 (ru) Специфичные в отношении прионов пептидные реагенты
HK1090275B (en) Prion-specific peptide reagents

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, US

Free format text: OLD OWNER(S): CHIRON CORPORATION

RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 04 SEP 2007; STATUS: REJECTED; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 29 NOV 2010; STATUS: OVERWRITTEN; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 14 JUL 2008; STATUS: REJECTED; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 14 OCT 2009; STATUS: REJECTED; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 11 NOV 2009; STATUS: REJECTED; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 26 MAY 2010; STATUS: REJECTED; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILING DATE: 24 DEC 2010; STATUS: SUPERSEDED; PUBLICATION DATE: 24 DEC 2010; TITLE: PRION-SPECIFIC PEPTIDE REAGENTS; FILI

Effective date: 20130225

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 AUG 2017 BY AJ PARK

Effective date: 20150130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2018 BY AJ PARK

Effective date: 20170529

LAPS Patent lapsed